Bhuyan K C, Bhuyan D K, Santos O, Podos S M
Department of Ophthalmology, Mount Sinai School of Medicine, City University of New York, NY 10029.
Free Radic Biol Med. 1992;12(4):251-61. doi: 10.1016/0891-5849(92)90112-t.
1-[(2s)-3-Mercapto-2-methylpropionyl]-L-proline (captopril), an antihypertensive and free radical scavenger, protected the rabbit lens from peroxidative and oxidative damage induced by 1 mM diquat in vitro. To evaluate the anticataract efficacy of captopril, an experimental group of five rabbits was treated with topical captopril (1% in 0.15 M NaCl, w/v), and 50 microliters was instilled onto both eyes four times a day for a total of 8 weeks. Following the same procedure, the eyes of five rabbits were treated with topical 0.15 M NaCl as a control for captopril treatment. At the end of the first week of treatment, a single intravitreal dose of 120 nmole diquat in 30 microliters of 0.15 M NaCl was injected into the right eye of each rabbit of both the groups. As a control for intravitreal diquat injection, the left eye of all the rabbits were injected with the diluent, 30 microliters per eye. The intravitreal diquat or its diluent injection was only for one time. From slit-lamp biomicroscopic observation of the diquat-injected right eyes, the anticataract effect of captopril in the treatment group was indicated by the finding that in four of five rabbits the cataract did not advance; whereas in four of five rabbits treated with the diluent the cataract progressed to grade 3. The lenses in the diluent-injected control left eyes of the rabbits treated with the captopril or diluent were normal. However, since the number of animals used for the in vivo studies was few, further confirmation of the anticataract effect of captopril is necessary. In diquat-injected right eyes of animals treated with captopril, the integrated rate of O2- production was about 50% less (p less than .001) in the aqueous humor, vitreous humor, and lens, compared with O2-, 33.49 +/- 2.26 microM (mean +/- SEM) in the aqueous humor, 17.12 +/- 0.75 microM in the vitreous humor, and 31.44 +/- 1.29 nmole/g wet weight in the lens of the diquat-injected right eyes treated with the diluent. Similar significant (p less than .01) differences in the production of .OH and H2O2 in eye tissues were also observed.(ABSTRACT TRUNCATED AT 400 WORDS)
1-[(2S)-3-巯基-2-甲基丙酰基]-L-脯氨酸(卡托普利)是一种抗高血压药和自由基清除剂,在体外可保护兔晶状体免受1 mM敌草快诱导的过氧化和氧化损伤。为评估卡托普利的抗白内障疗效,将5只兔作为实验组,用局部应用的卡托普利(0.15 M NaCl中1%,w/v)治疗,每天4次向双眼各滴入50微升,共8周。按照相同程序,将5只兔的眼睛用局部应用的0.15 M NaCl治疗作为卡托普利治疗的对照。在治疗第一周结束时,向两组每只兔的右眼玻璃体内注射单次剂量120纳摩尔敌草快于30微升0.15 M NaCl中。作为玻璃体内注射敌草快的对照,所有兔的左眼注射稀释剂,每只眼30微升。玻璃体内注射敌草快或其稀释剂仅一次。通过对注射敌草快的右眼进行裂隙灯生物显微镜观察发现,治疗组中5只兔有4只白内障未进展,提示卡托普利有抗白内障作用;而用稀释剂治疗的5只兔中有4只白内障进展到3级。接受卡托普利或稀释剂治疗的兔中,注射稀释剂的对照左眼晶状体正常。然而,由于用于体内研究的动物数量较少,卡托普利抗白内障作用还需进一步证实。在接受卡托普利治疗的动物注射敌草快的右眼中,房水、玻璃体和晶状体中O2-的产生综合速率比用稀释剂治疗的注射敌草快的右眼分别低约50%(p<0.001),后者房水中O2-为33.49±2.26微摩尔/升(平均值±标准误),玻璃体中为17.12±0.75微摩尔/升,晶状体中为31.44±1.29纳摩尔/克湿重。在眼组织中.OH和H2O2的产生也观察到类似的显著差异(p<0.01)。(摘要截断于400字)